Antibody–drug conjugates in solid tumors: a look into novel targets

Published on Jan 28, 2021in Journal of Hematology & Oncology11.059
· DOI :10.1186/S13045-021-01035-Z
Carmen Criscitiello14
Estimated H-index: 14
(IEO: European Institute of Oncology),
Stefania Morganti7
Estimated H-index: 7
(IEO: European Institute of Oncology),
Giuseppe Curigliano74
Estimated H-index: 74
(IEO: European Institute of Oncology)
Antibody-drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the "Trojan Horses" of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.
#1Saiama N. Waqar (WashU: Washington University in St. Louis)H-Index: 23
#2Mary W. Redman (Fred Hutchinson Cancer Research Center)H-Index: 28
Last. Vassiliki A. Papadimitrakopoulou (University of Texas MD Anderson Cancer Center)H-Index: 67
view all 17 authors...
Abstract Introduction Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET–positive squamous cell carcinoma (SCC). Patients and Methods Patients with previously treated SCC with c-MET–positive tumors (H score ≥ 150, Ventana SP44 assay) were enrolled into 2 cohorts: Cohort 1 (immune checkpoint inhibitor-naive) and Cohort 2 (immune checkpoint inhibitor refractory). Telisotuzumab vedotin 2.7 mg/kg was admi...
5 CitationsSource
#1Clinton Yam (University of Texas MD Anderson Cancer Center)H-Index: 8
#2Gaiane M. Rauch (University of Texas MD Anderson Cancer Center)H-Index: 14
Last. Stacy L. Moulder (University of Texas MD Anderson Cancer Center)H-Index: 42
view all 19 authors...
Folate receptor alpha (FRα) has been reported to be expressed in up to 80% of triple-negative breast cancers (TNBC) with limited expression in normal tissues, making it a promising therapeutic target. Mirvetuximab soravtansine (mirvetuximab-s) is an antibody drug conjugate which has shown promise in the treatment of FRα-positive solid tumors in early phase clinical trials. Herein, are the results of the first prospective phase II trial evaluating mirvetuximab-s in metastatic TNBC. Patients with ...
3 CitationsSource
#1Elaine Chang (CDER: Center for Drug Evaluation and Research)H-Index: 6
#2Chana Weinstock (CDER: Center for Drug Evaluation and Research)H-Index: 6
Last. Julia A. Beaver (FDA: Food and Drug Administration)H-Index: 25
view all 19 authors...
On December 18, 2019, the Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEV; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Substantial evidence of effectiveness for this application is obtained from Cohort 1 of the single ...
17 CitationsSource
#1Kevin Kalinsky (Columbia University)H-Index: 25
#2Jennifer R. Diamond (CU: University of Colorado Boulder)H-Index: 22
Last. Aditya Bardia (Harvard University)H-Index: 52
view all 16 authors...
Background Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody–drug conjugate composed of a humanized anti-Trop-2 monoclonal antibody coupled to SN-38 at a high drug-to-antibody ratio via a unique hydrolyzable linker that delivers SN-38 intracellularly and in the tumor microenvironment. SG was granted accelerated FDA approval for metastatic tr...
17 CitationsSource
#1Aditya BardiaH-Index: 52
#2Sara M. TolaneyH-Index: 47
Last. Sara A. Hurvitz (UCLA: University of California, Los Angeles)H-Index: 54
view all 20 authors...
28 CitationsSource
#1D.R. CamidgeH-Index: 29
#2Jonathan W. GoldmanH-Index: 43
Last. V. BlotH-Index: 1
view all 7 authors...
1 CitationsSource
#1Y. LoriotH-Index: 6
#2Arjun Vasant BalarH-Index: 20
Last. Petros GrivasH-Index: 22
view all 19 authors...
10 CitationsSource
#1Helena Alexandra Yu (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
#2Christina S BaikH-Index: 2
Last. Pasi A. JänneH-Index: 147
view all 17 authors...
7 CitationsSource
#1Robert L. ColemanH-Index: 79
#2Domenica LorussoH-Index: 11
Last. Bradley J. MonkH-Index: 51
view all 20 authors...
6 CitationsSource
Abstract Background Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based lin...
120 CitationsSource
Cited By8
#1Joyce F. Liu (Harvard University)H-Index: 40
#2Howard A. Burris (Sarah Cannon Research Institute)H-Index: 93
Last. Voleak Choeurng (Genentech)H-Index: 1
view all 12 authors...
Objectives null MUC16 is overexpressed in the majority of human epithelial ovarian cancers (OC). DMUC4064A is a humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. This trial assessed the safety, tolerability, pharmacokinetics, and preliminary activity of DMUC4064A in patients with platinum-resistant OC. null Methods null DMUC4064A was administered once every 3 weeks to patients in 1.0-5.6 mg/kg dose escalation cohorts, followed by coh...
#1Juliana T. W. TongH-Index: 1
#2Paul W. R. HarrisH-Index: 18
Last. Iman KavianiniaH-Index: 9
view all 4 authors...
The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemi...
#1Amanda Nash (Rice University)
#2Samira Aghlara-Fotovat (Rice University)H-Index: 1
Last. Omid Veiseh (Rice University)H-Index: 42
view all 5 authors...
Abstract null null Immunomodulatory therapeutics represent a unique class of drug products that have tremendous potential to rebalance malfunctioning immune systems and are quickly becoming one of the fastest-growing areas in the pharmaceutical industry. For these drugs to become mainstream medicines, they must provide greater therapeutic benefit than the currently used treatments without causing severe toxicities. Immunomodulators, cell-based therapies, antibodies, and viral therapies have all ...
#1Takamichi Ito (Kyushu University)H-Index: 16
#2Keiko Tanegashima (Kyushu University)
Last. Yumiko Kaku-Ito (Kyushu University)H-Index: 4
view all 7 authors...
Extramammary Paget's disease (EMPD) is a rare skin cancer arising in the apocrine gland-rich areas. Most EMPD tumors are dormant, but metastatic lesions are associated with poor outcomes owing to the lack of effective systemic therapies. Trophoblast cell surface antigen 2 (Trop2), a surface glycoprotein, has drawn attention as a potential therapeutic target for solid tumors. Sacituzumab govitecan, an antibody-drug conjugate of Trop2, has recently entered clinical use for the treatment of various...
1 CitationsSource
#1E Adams (Katholieke Universiteit Leuven)
#2Hans Wildiers (Katholieke Universiteit Leuven)H-Index: 67
Last. Kevin Punie (Katholieke Universiteit Leuven)H-Index: 10
view all 4 authors...
Background null Two new antibody–drug conjugates (ADCs) containing a topoisomerase I inhibitor payload have recently emerged in the breast cancer (BC) treatment landscape. Sacituzumab govitecan-hziy (SG) is a first-in-class anti-trophoblast cell-surface antigen 2 ADC approved for pretreated metastatic triple-negative breast cancer (mTNBC) and trastuzumab deruxtecan (T-DXd) gained approval for human epidermal growth factor receptor-2 (HER2)-positive advanced BC (aBC). We aim to provide a contempo...
#1Chiara Corti (IEO: European Institute of Oncology)H-Index: 6
Metastatic breast cancer (BC) is currently an incurable disease. Besides endocrine therapy and targeted agents, chemotherapy is often used in the treatment of this disease. However, lack of tumor specificity and toxicity associated with dose exposure limit the manageability of cytotoxic agents. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer drugs. By merging the selectivity of monoclonal antibodies with the cytotoxic properties of chemotherapy, they improve the therapeu...
#1Francesco Schettini (University of Naples Federico II)H-Index: 12
Last. S. Guedan
view all 9 authors...
Background Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody–drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal tissues. To identify new targets for ADCs and CAR-T specifically targeting breast cancer (BC) molecular and pathology-based subtypes, we propose a novel in silico strategy based on multiple publicly a...
2 CitationsSource